Gene therapy designed to initiate apoptotic cell death provides a potentially effective method to treat cancer. A prerequisite for this approach is the identification of genes that function in distinct apoptotic pathways. Although apoptotic pathways initiated by receptors such as tumor necrosis factor receptor-1 are well characterized, little is known about apoptotic pathways initiated within the nucleus in response to genotoxic stress. We have demonstrated previously that the nuclear, death domain-containing protein p84N5 can induce apoptosis upon transfection into cells, suggesting that it may play a role in an apoptotic pathway initiated within the nucleus. To test the possibility that N5 could be used in the gene therapy of cancer, we have generated a recombinant adenovirus engineered to express N5 and tested the effects of viral infection on the growth and tumorigenicity of tumor cells. N5 adenovirus infection significantly reduced the proliferation and tumorigenicity of breast, ovarian, and osteosarcoma tumor cell lines. Reduced proliferation and tumorigenicity were mediated by an induction of apoptosis as indicated by DNA fragmentation in infected cells. The results suggest that the N5 cDNA is a candidate for the gene therapy of cancer. Cancer Gene Therapy (2000) 7, 985-990
C
ancer is a result of defects in the coordination of cell proliferation and programmed cell death. The extent of cell death is physiologically controlled by the activation of a programmed suicide pathway that results in a morphologically recognizable form of death termed apoptosis. 1, 2 Inducing apoptosis in tumor cells by gene therapy provides a potentially effective means to treat cancer. 3 To maximize the effectiveness of this approach, identifying genes that play a role in a variety of distinct apoptotic pathways is required. The apoptotic pathways initiated by death receptors such as tumor necrosis factor receptor-1 or Fas ligand receptor are relatively well characterized. 4 Less is known about how apoptotic pathways initiated in the nucleus in response to DNA damage function.
The N5 cDNA was cloned based on the ability of its encoded protein to bind an amino terminal domain of the retinoblastoma gene (RB) product. N5 encodes a nuclear protein with an apparent molecular mass of 84 kDa. 5 N5 protein (p84N5) contains a sequence similarity to the death domains of other proteins involved in the regulation of apoptosis. 6 Transfection of N5 expression vectors can induce apoptotic cell death that is dependent upon an intact death domain and is inhibited by coexpression of RB. 7 Furthermore, dominant interfering mutants of N5 inhibit the normal response of cells to ionizing radiation. These observations suggest that N5 may play a role in a novel apoptotic pathway initiated within the nucleus in response to genotoxic agents. RB is known to inhibit apoptosis by a variety of triggers, including radiation; 8 p84N5 could mediate these effects. Because N5 may be involved in a novel apoptotic pathway regulated by RB and because defects in the RB regulatory pathway occur in many, if not all, 9 human tumors, we have tested the potential of N5 as a gene therapy for cancer. We have generated a recombinant adenovirus (AdN5) designed to express N5 under control of the cytomegalovirus early promoter and have tested the effects of AdN5 infection on the growth and tumorigenicity of five tumor cell lines.
MATERIALS AND METHODS

Cell line and cell culture
All cell lines were obtained from the American Type Culture Collection (Manassas, Va) and maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine sera and antibiotics (100 U/mL penicillin, 100 g/mL streptomycin) in a 5% CO 2 incubator at 37°C.
Recombinant adenovirus preparation and infection
The recombinant p84N5 adenovirus is a modified serotype 5 adenovirus. The full-length N5 cDNA was cloned into the E1-deleted transfer vector pAdCMV(AS)-BGHpA (a gift of Dr. T. J. Liu, MD Anderson Cancer Center) containing the cytomegalovirus early promoter and bovine growth hormone polyadenylation signal. AdN5 was isolated by electroporation of the N5 transfer vector with pJM17 into 293 cells as described previously. 10 The control wild-type (wt) RB and green fluorescent protein (GFP)-expressing adenovirus were similarly constructed. Large-scale viral preps were harvested from cells at 36 -40 hours postinfection by resuspension in phosphate buffered saline (PBS) and lysis by freeze-thaw. Virus was purified from the cleared lysate by CsCl equilibrium density gradient centrifugation, and viral particles were quantitated by spectrophotometry as described previously.
11 Infectious titer was estimated by an end point assay using the adenovirus direct immunofluorescence kit (Chemicon International, Temecula, Calif). The concentrated virus was dialyzed against PBS plus 10% glycerol, aliquoted, and stored at Ϫ80°C. Infection was carried out by addition of the virus to the culture media and continued incubation at 37°C for the desired length of time.
Western blot analysis
Infected cells were lysed in 50 mM tris(hydroxymethyl)aminomethane (Tris) (pH 7.4), 250 mM NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 0.1% Nonidet P-40, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 g/mL leupeptin on ice for 10 minutes. Cell debris was pelleted by centrifugation, and the total protein concentration of the soluble extract was determined by Bradford assay according to the manufacturer's instructions (Bio-Rad, Hercules, Calif). A total of 17 g of total protein for each sample was resolved by a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel. The proteins were transferred to a nitrocellulose membrane, and the membrane was blocked with 5% dry milk in PBS. The blot was stained with a mouse anti-human p84N5 monoclonal antibody (mAb) 5 and mouse anti-human ␤-actin mAb. The blot was developed by enhanced chemiluminescence using a horseradish peroxidase-conjugated rabbit anti-mouse immunoglobulin G as described by the manufacturer (Amersham Life Science, Arlington Heights, Ill).
Cell growth assay
Cells were plated at a density of 2 ϫ 10 4 cells/mL in 12-well plates in triplicate. Cells were infected with either AdN5 or AdGFP at a multiplicity of infection (MOI) of 10 for all cell lines, except for the SKOV3 IP-1 cell line, which was infected at an MOI of 50. Cells were harvested at the indicated time intervals and stained with trypan blue; viable cells were counted using a hemocytometer.
Tumorigenicity assays
SKOV3 IP-1 cells were infected overnight at an MOI of 50 with AdN5 or AdGFP or were left untreated. U2OS cells were similarly infected at an MOI of 10. The cells were harvested by trypsinization, an aliquot of each sample was stained with trypan blue, and the number of viable cells was determined. One million cells of each sample were washed twice with PBS, and the cells in a final volume of 0.2 mL were injected subcutaneously (s.c.) into the flanks of nude mice. Tumor formation was evaluated weekly for 5 weeks. At least six mice were injected for each sample. Tumor volumes were estimated by measuring the diameter of the resulting tumors in three dimensions.
DNA fragmentation analysis
After infection with AdN5 or AdGFP for 5 days, cells were collected and resuspended in 0.1 mL of PBS, to which 1 mL of extraction buffer (10 mM Tris (pH 8.0), 0.1 M EDTA, 20 g/mL ribonuclease, 0.5% SDS) was added before incubation at 37°C for 1-2 hours. Proteinase K was then added to a final concentration of 100 g/mL and the samples were incubated for an additional 3 hours at 50°C. NaCl was added to bring up the final Na ϩ concentration to 1 M, and the samples were incubated overnight at 4°C. The high molecular weight DNA was pelleted by centrifugation for 1 hour at 57,000 ϫ g. The supernatant was extracted once with an equal volume of 0.5 M Tris (pH 8.0)-saturated phenol and then again with phenol/ chloroform. The precipitated DNA was resolved by a 1% agarose gel and stained with ethidium bromide.
RESULTS
Five tumor cell lines were used to study the effects of AdN5 infection: two breast carcinoma lines (MCF-7 and MDA-MB-453), an ovarian carcinoma line (SKOV3 IP-1), and two osteosarcoma cell lines (SAOS-2 and U2OS). To test the sensitivity of these cell lines to adenoviral infection, each cell line was treated with varying numbers of infectious, recombinant virus designed to express GFP (AdGFP). The percentage of infected cells was determined the following day by fluorescence microscopy. At an MOI of 10, Ͼ90% of MDA-MB-453, MCF-7, U2OS, or SAOS-2 cells expressed detectable GFP (Fig 1) . An MOI of 50 was required to observe similar levels of infection in SKOV3 IP-1 cells. For all subsequent experiments, an MOI of 50 was used to treat SKOV3 IP-1 cells, whereas an MOI of 10 was used to treat the remaining cell lines. Because the infectious titer of both AdGFP and AdN5 viral stocks was determined by infection of 293 cells (see Materials and Methods), the gene transduction efficiency for each of the viruses in each of the cell lines should be similar.
We characterized the level of p84N5 expression after treatment with AdN5 or AdGFP by Western blot analysis of protein extracts from treated SKOV3 IP-1 or U2OS cells (Fig 2) . An equal mass of total cell protein from each sample was resolved by SDS-PAGE and blotted; the Western blots were stained with a mAb specific for p84N5 or ␤-actin. The amount of p84N5 detected in untreated or AdGFP-treated cells of both cell lines was approximately the same relative to the ␤-actin loading control, indicating that AdGFP infection did not alter p84N5 expression. However, AdN5-infected U2OS or SKOV3 IP-1 cells contained 2-to 3-fold more p84N5 by 24 hours postinfection. This level of expression increased slightly by 48 hours postinfection.
To determine the effect of AdN5 infection and increased p84N5 expression on the proliferation of each cell line in vitro, growth curves were measured for each of the five cell lines treated with AdN5, AdGFP, or PBS. Infection with AdN5 inhibited the cell proliferation of each cell line (Fig 3A) . By the day 2 postinfection, lower numbers of cells were consistently observed in cells treated with AdN5. The cell number in AdN5-treated cultures remained relatively constant until day 3 or day 4, at which point the cell number declined. By day 5, few viable cells treated with AdN5 remained. In contrast, cells treated with PBS or AdGFP continued to proliferate until reaching confluency around day 5. Treatment of cells with AdGFP had no detectable effect on cell proliferation relative to PBS cells. The effect of AdN5 infection on the tumorigenicity of SKOV3 IP-1 and U2OS in nude mice was also examined. Viable cells infected with AdN5 or AdGFP for 16 hours were injected s.c. into the flanks of nude mice. Both AdGFPand PBS-treated SKOV3 IP-1 cells formed large tumors that were readily detectable by 2 weeks postinjection (Fig 3B) . Tumor volume increased exponentially over time. Consistent with our in vitro proliferation data, no tumor growth could be detected in SKOV3 IP-1 cells treated with AdN5 even after 5 weeks. At this time, the tumor volume of AdGFP-infected cells reached 600 mm 3 . Similar results were observed in U2OS cells. The tumor volume of AdGFP-and PBS-treated U2OS cells reached a maximum of 43 mm 3 , whereas no tumor growth could be detected in AdN5-infected cells (data not shown).
Our previous work had indicated that transfection of p84N5 expression vectors could inhibit cell proliferation by induction of apoptosis, and that coexpression of RB blocked this effect. 7 The cell lines examined here vary with respect to expression of endogenous RB. For example, MCF-7 and U2OS express wt RB but SAOS-2 does not. Yet each of these cell lines is equally sensitive to AdN5. This may be due to the relative levels of p84N5 versus RB expression in AdN5-treated cells. To examine this possibility, we measured the proliferation of cells treated with AdN5 and a recombinant adenovirus designed to express RB protein. Consistent with our previous assay, cells treated with PBS or AdGFP proliferate exponentially, whereas AdN5-treated cells proliferate slower until day 3, at which point cell numbers begin to decline. Like AdN5-treated cells, cells treated with both AdN5 and AdRB proliferate slower initially (Fig 4A) . However, the number of AdN5-plus AdRB-treated cells does not decline at later times like cells treated with AdN5 alone (Fig 4B) . Treatment of cells with AdRB alone also causes cell proliferation to slow substantially, consistent with the documented ability of RB protein to induce cell cycle arrest. 12 To determine whether AdN5 infection, like N5 gene transfection, inhibited tumor cell proliferation by induction of apoptotic cell death, DNA was extracted from cells 4 or 5 days after infection with AdN5, AdGFP, or PBS. The DNA was resolved by agarose gel electrophoresis and stained with ethidium bromide. DNA fragmentation resulting in laddering, which is characteristic of cells undergoing apoptosis, was observed in AdN5-infected cells, but not in cells treated with AdGFP or PBS (Fig 5) . Using a terminal deoxytransferase end labeling reaction, we have determined that Ͼ80% of cells treated with AdN5 contain fragmented DNA at 3 days postinfection, whereas only 7% of AdGFP-infected cells contain fragmented DNA (data not shown). The morphology of AdN5-infected cells at this time was also consistent with induction of apoptosis. Relative to AdGFP-infected cells, AdN5-infected cells exhibit a condensed and rounded morphology before detaching from the culture dish (data not shown).
DISCUSSION
We demonstrate in this study that adenovirus-mediated N5 gene transfer can increase the expression of p84N5. The increase in p84N5 expression is modest relative to that achievable with other proteins using similarly constructed recombinant adenovirus. This observation may, in part, be due to the fact that p84N5 is likely targeted for degradation during the induction of apoptosis. 7 Cells expressing high levels of p84N5, therefore, are triggered to undergo apoptosis, resulting in p84N5 degradation and in decreased levels of detectable p84N5. Indeed, examination of p84N5 expression in AdN5 infected cells at 3-4 days postinfection, when most cells are undergoing apoptosis, reveals lower levels of p84N5 than uninfected cells (S.Y., unpublished observation). In any case, 5) , cells at 24 hours after infection with AdGFP (lanes 2 and 6) or AdN5 (lanes 3 and 7) , and cells at 48 hours after infection with AdN5 (lanes 4 and 8) were extracted; next, 17 g of total protein from the cleared lysates was resolved by 10% SDS-PAGE, blotted to nitrocellulose, and probed with an antibody specific for N5 protein or a mouse anti-␤-actin mAb. The position of molecular weight standards and ␤-actin are indicated.
YIN, HUNG, AND GOODRICH: N5 ADENOVIRUS INDUCES APOPTOSIS IN CANCER CELLS
the increase in p84N5 expression upon AdN5 infection is sufficient to inhibit the proliferation of several different types of tumor cells both in vitro and in vivo. Inhibition of cell proliferation is not a consequence of adenoviral infection itself, because treatment of cells with AdGFP had no detectable effect on cells relative to mock- . This observation may explain the initial cytostatic effect of AdN5 that is followed by apoptosis. Therefore, N5-induced apoptosis may be a late event that follows a G 2 /M block to cell cycle progression. This behavior is reminiscent of cellular responses to ionizing radiation.
We have observed previously that coexpression of RB can inhibit N5-induced apoptosis, and that their physical association mediates this block. 7 However, all of the cell lines tested in this study are sensitive to AdN5 yet vary in their RB status. For example, MCF-7 and U2OS cells contain apparently wt RB yet are as sensitive to AdN5 as cells lacking RB, such as SAOS-2 and SKOV3 IP-1. This apparent contradiction may be explained by the fact that sufficient endogenous RB protein is not expressed in these cells lines to block the apoptosis triggered by AdN5-mediated p84N5 expression. Consistent with this, treatment of cells with AdN5 and AdRB inhibits cell proliferation but delays the rapid decline in cell numbers that occurs in cells treated with AdN5 alone. This observation is consistent with the explanation that RB expression inhibits AdN5-induced apoptosis and cell proliferation due to its well-characterized ability to induce cell cycle arrest. Therefore, cells with wt RB protein, including noncancerous cells, may be less sensitive to AdN5 than RB-negative tumor cells. Additional in vivo studies as well as in vitro studies using "normal cells" will be required to test this hypothesis. Because several different cell lines of different tissue origin were equally sensitive to AdN5, the inhibition of cell proliferation observed is not cell line-or tissuespecific. Interestingly, all of the cell lines tested, except MCF-7, lack wt p53. This indicates that N5-induced apoptosis is independent of p53. MCF-7 cells, conversely, lack functional caspase-3, 13 yet these cells are sensitive to N5-mediated apoptosis. Hence, caspase-3 is not required for N5-induced apoptosis. The mechanism 1-3) or U2OS cells (lanes 4 -6) were treated with PBS (lanes 1 and 4), AdGFP (lanes 2 and 5), or AdN5 (lanes 3 and 6) at MOIs of 50 or 10, respectively. After 5 days, cells were collected and resuspended in 0.1 mL of PBS to which 1 mL of 10 mM Tris (pH 8.0), 100 mM EDTA, 20 g/mL ribonuclease, and 0.5% SDS was added before incubation at 37°C for 1-2 hours. Proteinase K was then added to a final concentration of 100 g/mL and incubation continued at 50°C for at least 3 hours. NaCl was added to a final concentration of 1 M and the samples were incubated at 4°C overnight. High molecular weight DNA was pelleted by ultracentrifugation for 1 hour at 57,000 ϫ g. The supernatant was extracted once with an equal volume of 0.5 M Tris (pH 8.0)-saturated phenol and then again with phenol/chloroform. The DNA was ethanolprecipitated and analyzed in a 1% agarose gel. A 1-kbp DNA ladder served as the molecular weight (MW) marker.
of N5-induced cell death is uncharacterized. However, several observations indicate that AdN5 activates an apoptotic pathway that is distinct from those activated by other recombinant adenovirus that can induce apoptosis in tumor cells such as Adp53, AdE2F-1, AdPML, or AdFas ligand. 14 -17 For example, in contrast to AdN5, cells containing wt p53 are less sensitive to Adp53 than cells lacking wt p53. 18 Furthermore, Adp53 and AdPML infection induces G 1 cell cycle arrest and subsequent apoptosis, 15, 19 whereas AdE2F-1 infection induces premature entry into S phase. 20 In contrast, AdN5 causes a G 2 /M cell cycle arrest followed by apoptosis (J. Doostzadeh-Cizeron, unpublished observations). Although N5 contains sequence similarity to other death domaincontaining proteins that induce apoptosis, it is likely to function differently because it is localized exclusively to the nucleus during interphase. These observations suggest that adenoviral-mediated N5 gene transfer induces a novel apoptotic pathway. We conclude that N5 is an attractive candidate for gene therapy of cancer; further studies are warranted to test its potential efficacy.
